Daiichi Told Cancer Drug Patent Fight Must Be Arbitrated
Law360 (May 1, 2020, 7:54 PM EDT) -- An arbitrator has concluded that a dispute between Daiichi Sankyo Co. Ltd. and a U.S. biotechnology company over cancer drug patents should be arbitrated, saying he was obligated to do so since it was not obvious whether the dispute fell under an exclusion in the parties' agreement.
The arbitrator, Judge Garrett E. Brown Jr., who is retired, concluded that Seattle Genetics Inc.'s argument that the dispute fell under the arbitration clause in its agreement with Daiichi Sankyo was "at least as plausible" as the Japanese pharmaceutical company's argument that the dispute was excluded from arbitration under the deal.
The clause includes...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!